Key result
Incretin-based therapies improve symptoms, weight, and cardiovascular outcomes in patients with obesity and HFpEF.
Why the study?
GLP-1 RAs and emerging dual incretin therapies show substantial metabolic and weight benefits with growing evidence of cardiovascular efficacy, but evidence spans heterogeneous study designs across obesity, diabetes, and HFpEF.
Do GLP-1 receptor agonists and dual incretin therapies improve cardiovascular and HFpEF-related outcomes in patients with obesity?
Do GLP-1 receptor agonists and dual incretin therapies improve cardiovascular and HFpEF-related outcomes in patients with obesity?
GLP-1 receptor agonists and dual incretin therapies are emerging as effective phenotype-directed strategies for managing obesity-related HFpEF and reducing cardiovascular risk.
May support evaluation in obesity-HFpEF; leaves open optimal dosing and confirmatory RCTs.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and emerging dual incretin therapies have demonstrated substantial effects on weight reduction and metabolic improvement, with growing evidence supporting favorable cardiovascular outcomes. This narrative review provides a focused overview of key cardiovascular outcomes trials (CVOTs) and HFpEF-oriented clinical studies evaluating GLP-1 RA and dual incretin therapies in patients living with obesity, including completed and ongoing investigations. We summarize trial characteristics, critically appraise their outcomes, and briefly discuss mechanistic pathways potentially linking incretin-based therapies to cardiovascular and HFpEF-related benefits. Because available data derive from heterogeneous study designs, we explicitly distinguish evidence from type 2 diabetes cardiovascular outcomes trials, obesity-without-diabetes cardiovascular outcomes trials, HFpEF-specific randomized trials, mechanistic substudies, ongoing trials, and real-world observational analyses. We also situate incretin-based therapies within contemporary obesity, diabetes, cardiovascular, and HFpEF guideline-directed care. Finally, we identify current knowledge gaps, future research priorities, and innovative approaches needed to refine personalized therapeutic strategies and optimize patient-centered outcomes in obesity-associated HFpEF.
No takes yet. Share an insight, caveat, or question.
Belančić et al. (2026) conducted a review in Obesity, Heart Failure with Preserved Ejection Fraction (HFpEF), and Cardiovascular Disease. GLP-1 receptor agonists and dual incretin therapies vs. Placebo or standard care (across reviewed studies) was evaluated. GLP-1 receptor agonists and dual incretin therapies demonstrate substantial benefits in weight reduction, symptom improvement, and cardiovascular outcomes for patients with obesity and HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: